Christopher Arthur

3.3k citations
46 papers · 2.0k · 2 hit papers · h-index 15

Impact in

  • Hematology top 0.5%
    • Chronic Myeloid Leukemia Treatments
    • Acute Myeloid Leukemia Research
    • Hematopoietic Stem Cell Transplantation
  • Genetics top 1%
    • Chronic Lymphocytic Leukemia Research
    • Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

  • Hematology 29
    • Chronic Myeloid Leukemia Treatments 23
    • Acute Myeloid Leukemia Research 10
  • Genetics 22
    • Chronic Lymphocytic Leukemia Research 21
Co-authors
Timothy P. Hughes (12 shared papers)Andrew Grigg (13 shared papers)Anthony P. Schwarer (11 shared papers)Susan Branford (11 shared papers)John F. Seymour (10 shared papers)Robin Filshie (9 shared papers)Anthony K. Mills (7 shared papers)David M. Ross (6 shared papers)
Journals
Blood (16 papers)Journal of Clinical Oncology (4 papers)Bone Marrow Transplantation (3 papers)Leukemia (2 papers)Pathology (2 papers)
Partner nations
AustraliaUnited StatesFrance

In The Last Decade

Christopher Arthur

44 papers receiving 1.9k citations

Christopher Arthur's Hit Papers

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study 2013 · 508 citations
5080+4+9Years since publication250500750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2013 Blood
  2. 2012 Journal of Clinical Oncology

Peers

Christopher Arthur
Comparison fields: 5 of 84
  • Hematology 1.7k
  • Genetics 954
  • Rheumatology 477
  • Oncology 348
  • Public Health, Environmental and Occupational Health 326
Replace G. Alimena with:
G. Alimena Italy
Gareth Gerrard United Kingdom
Ester Orlandi Italy
Valentín García‐Gutiérrez Spain
Rolf Billström Sweden
Saengsuree Jootar Thailand
Anthony K. Mills Australia
Thomas Cluzeau France
Ester Pungolino Italy
Helmut Löffler Germany
Christopher Arthur relative to G. Alimena Italy G. Alimena's profile →
Citations per field
00.5×2×4×6×7.7×
G. Alimena · 1×
Citations per year

Countries citing papers authored by Christopher Arthur

Since Specialization
Citations

This map shows the geographic impact of Christopher Arthur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Arthur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Arthur more than expected).

Fields of papers citing papers by Christopher Arthur

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Arthur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Arthur. The network helps show where Christopher Arthur may publish in the future.

Co-authors

The 25 scholars most cited alongside Christopher Arthur, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christopher Arthur Line = papers co-authored together Christopher Arthur links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 46 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Journal of Clinical Oncology ·Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska, Agnieszka Wierzbowska, Grzegorz Mazur, Jiří Mayer, Jyh-Pyng Gau, Wen‐Chien Chou, Rena Buckstein, Jaroslav Čermák, Ching-Yuan Kuo, Albert Oriol, Farhad Ravandi, Stefan Faderl, Jacques Delaunay, Daniel Lysák, Mark D. Minden, Christopher Arthur
Hit paper breakdown →		2012818
2
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
Blood ·David M. Ross, Susan Branford, John F. Seymour, Anthony P. Schwarer, Christopher Arthur, David T Yeung, Phuong Dang, Jarrad M. Goyne, Cassandra Slader, Robin Filshie, Anthony K. Mills, Junia V. Melo, Deborah L. White, Andrew Grigg, Timothy P. Hughes
Hit paper breakdown →		2013508
3
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
Leukemia ·David M. Ross, Susan Branford, John F. Seymour, Anthony P. Schwarer, Christopher Arthur, P. A. Bartley, Cassandra Slader, Catherine J. Field, P Dang, Robin Filshie, Anthony K. Mills, Andrew Grigg, J V Melo, Timothy P. Hughes
2010194
4
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
Leukemia ·(unknown), David M. Ross, Ilaria S. Pagani, Naranie Shanmuganathan, Chung Hoow Kok, John F. Seymour, Anthony K. Mills, Robin Filshie, Christopher Arthur, Phuong Dang, Verity A Saunders, Jodi Braley, Agnes S. M. Yong, David T Yeung, Deborah L. White, Andrew Grigg, Anthony P. Schwarer, Susan Branford, Timothy P. Hughes
201856
5
Combined Interferon Alfa-2a and Cytosine Arabinoside as First-Line Treatment for Chronic Myeloid Leukemia
Acta Haematologica ·Christopher Arthur, D.D.F. Ma
199340
6
Use of minisatellite DNA probes for recognition and characterization of relapse after allogeneic bone marrow transplantation
British Journal of Haematology ·Gao Ling Min, Jill Hibbin, Christopher Arthur, Jane F. Apperley, Alec J. Jeffreys, John M. Goldman
198834
7
Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics
BMC Cancer ·Jiřı́ Mayer, Christopher Arthur, Jacques Delaunay, Grzegorz Mazur, Xavier Thomas, Agnieszka Wierzbowska, Farhad Ravandi, Erhan Berrak, Mark M. Jones, Yuhan Li, Hagop M. Kantarjian
201431
8
Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial
Blood ·David T Yeung, Michael Osborn, Deborah L. White, Susan Branford, Michael Kornhauser, Cassandra Slader, Samar Issa, Devendra Hiwase, Mark Hertzberg, Anthony P. Schwarer, Robin Filshie, Christopher Arthur, Yiu Lam Kwan, Cecily Forsyth, David M. Ross, Anthony K. Mills, Andrew Grigg, Timothy P. Hughes
201123
9
The heparin induced thrombosis — thrombocytopenia syndrome (H.I.T.T.S.): A review
Pathology ·Christopher Arthur, James P. Isbister, E.M. Aspery
198521
10
Higher-Dose Imatinib (600 mg/Day) with Selective Intensification in Newly Diagnosed CML Patients in Chronic Phase; Cytogenetic Response Rates at 12 Months Are Superior to IRIS.
Blood ·Timothy P. Hughes, Susan Branford, John Reynolds, John F. Seymour, Kerry Taylor, Nancy Guzzo-Pernell, Robin Filshie, Christopher Arthur, Anthony P. Schwarer, Mark Hertzberg, Zbigniew Rudzki, Michael Copeman, Kevin Lynch, Andrew Grigg
200420
11
A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Clinical Lymphoma Myeloma & Leukemia ·Xavier Thomas, Christopher Arthur, Jacques Delaunay, Mark M. Jones, Erhan Berrak, Hagop M. Kantarjian
201317
12
The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.
Blood ·Davi D M Ross, Andrew Grigg, Anthony P. Schwarer, Christopher Arthur, Kerryn Loftus, Anthony K. Mills, Robin Filshie, Ruth Columbus, John Reynolds, John F. Seymour, Susan Branford, Timothy P. Hughes
200817
13
Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study
Blood ·Giuseppe Gritti, Paula Marlton, Tycel Phillips, Christopher Arthur, Rajat Bannerji, Paolo Corradini, Anna Johnston, John F. Seymour, Sam Yuen, Jamie Hirata, Lisa Musick, Sourish Saha, Brandon Croft, Christopher R. Flowers
202016
14
Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.
Journal of Clinical Oncology ·Jörge E. Cortes, Elza Lomaia, Anna Turkina, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Christine Rojas, Charles Chuah, Christopher Arthur, Jane Apperley, Dong‐Wook Kim, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Michael J. Mauro, Jeffrey H. Lipton, Daniel Naranjo, Guohui Liu, Shouryadeep Srivastava, Michael W. Deininger
202016
15
Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response.
Blood ·Susan Branford, Rebecca Lawrence, Andrew Grigg, John F. Seymour, Anthony P. Schwarer, Christopher Arthur, Zbigniew Rudzki, Timothy P. Hughes
200815
16
Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome
SHILAP Revista de lepidopterología ·Yandong Shen, Luke Coyle, Ian Kerridge, William Stevenson, Christopher Arthur, Naomi McKinlay, Keith Fay, Christopher Wård, Matthew Greenwood, Giles Best, Ann Solterbeck, Alexander Guminski, Stephen Shumack, Stephen P. Mulligan
202114
17
Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial
Blood ·David T Yeung, Michael Osborn, Deborah L. White, Susan Branford, Michael Kornhauser, Cassandra Slader, Samar Issa, Devendra Hiwase, Mark Hertzberg, Anthony P. Schwarer, Robin Filshie, Christopher Arthur, Yiu Lam Kwan, Cecily Forsyth, David M. Ross, Anthony K. Mills, Andrew Grigg, Timothy P. Hughes, (unknown)
201214
18
Allogeneic haemopoietic cell transplants in Australia, 1996 – A multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow
Bone Marrow Transplantation ·Ian Nivison‐Smith, KF Bradstock, Jeff Szer, Simon Durrant, Anthony J. Dodds, Rick Hermann, AP Schwarer, John Gibson, LB To, Christopher Arthur, (unknown)
200113
19
Effects of taipan (Oxyuranus scutellatus) venom on erythrocyte morphology and blood viscosity in a human victim in vivo and in vitro
Transactions of the Royal Society of Tropical Medicine and Hygiene ·Christopher Arthur, Dugald McCallum, Diane J. Loveday, Anne T. Collins, James P. Isbister, M. McD. Fisher
199112
20
BCR-ABL Levels Continue To Decrease up to 42 Months after Commencement of Standard Dose Imatinib in Patients with Newly Diagnosed Chronic Phase CML Who Achieve a Major Molecular Response.
Blood ·Susan Branford, Zbigniew Rudzki, Andrew Grigg, John F. Seymour, Kerry Taylor, Peter Browett, Anthony P. Schwarer, Ken Bradstock, Christopher Arthur, Simon Durrant, Dan Ma, David Joske, Kevin Lynch, Timothy P. Hughes
200410

About Christopher Arthur

Christopher Arthur is a scholar working on Hematology, Genetics, Oncology, Public Health, Environmental and Occupational Health and Pathology and Forensic Medicine, having authored 46 papers that have together received 2.0k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (23 papers), Chronic Lymphocytic Leukemia Research (21 papers), Acute Myeloid Leukemia Research (10 papers), Acute Lymphoblastic Leukemia research (8 papers), Lymphoma Diagnosis and Treatment (8 papers), Eosinophilic Disorders and Syndromes (7 papers), Histone Deacetylase Inhibitors Research (3 papers) and Neutropenia and Cancer Infections (3 papers). The work is most often cited by research in Hematology (1.7k citations), Genetics (954 citations), Rheumatology (477 citations), Oncology (348 citations) and Public Health, Environmental and Occupational Health (326 citations). Christopher Arthur has collaborated with scholars based in Australia, United States and France. Frequent co-authors include Timothy P. Hughes, Andrew Grigg, Anthony P. Schwarer, Susan Branford, John F. Seymour, Robin Filshie, Anthony K. Mills, David M. Ross, Xavier Thomas and Hagop M. Kantarjian. Their work appears in journals such as Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, Leukemia and Pathology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G. AlimenaBreakdown of academic impact, for papers by Gareth GerrardBreakdown of academic impact, for papers by Ester OrlandiBreakdown of academic impact, for papers by Valentín García‐GutiérrezBreakdown of academic impact, for papers by Rolf BillströmBreakdown of academic impact, for papers by Saengsuree JootarBreakdown of academic impact, for papers by Anthony K. MillsBreakdown of academic impact, for papers by Thomas CluzeauBreakdown of academic impact, for papers by Ester PungolinoBreakdown of academic impact, for papers by Helmut Löffler